keyword
MENU ▼
Read by QxMD icon Read
search

Hematopoietic stem cell transplantation

keyword
https://www.readbyqxmd.com/read/29684567/human-herpesvirus-6b-hhv-6b-reactivation-is-a-risk-factor-for-grade-2-4-acute-graft-versus-host-disease-agvhd-after-hematopoietic-stem-cell-transplantation-hct-a-systematic-review-and-meta-analysis
#1
REVIEW
Tuan L Phan, Kristen Carlin, Per Ljungman, Ioannis Politikos, Vicki Boussiotis, Michael Boeckh, Michele L Shaffer, Danielle M Zerr
BACKGROUND/OBJECTIVE: Graft-versus-host disease (GVHD) is an important cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT). Many studies have suggested that HHV-6B plays a role in acute GVHD (aGVHD) following HCT. Our objective was to systematically summarize and analyze evidence regarding HHV-6B reactivation and development of aGVHD. METHODS: PubMed and EMBASE databases were searched using terms for HHV-6, HCT, and aGVHD, yielding 865 unique results...
April 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29684566/eltrombopag-for-the-treatment-of-of-refractory-pure-red-cell-aplasia-after-major-abo-incompatible-hematopoietic-stem-cell-transplantation
#2
Alessandro Busca, Chiara Dellacasa, Luisa Giaccone, Sara Manetta, Lucia Biale, Laura Godio, Semra Aydin, Moreno Festuccia, Lucia Brunello, Benedetto Bruno
Pure red cell aplasia (PRCS) is a well-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT). Many therapeutic options are available to treat this condition, including erythropoietin, rituximab, bortezomib, plasma exchange, immunoadsorption, donor lymphocyte infusion, mesenchymal stem cells, anti-thymocyte globulin and high-dose steroids; however treatment outcomes are often variable and can sometimes lead to disappointing results. In this brief article we report our experience with two patients with PRCA after major AB0-incompatible HSCT who were resistant to multiple therapeutic interventions and who eventually benefited from treatment with eltrombopag, a thrombopoietin mimetic approved by the Food and Drug Administration for the treatment of patients with immune thrombocytopenic purpura or severe aplastic anemia (SAA), refractory to immunosuppressive agents or not eligible to HSCT...
April 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29684565/thiotepa-based-intensified-reduced-intensity-conditioning-adult-double-unit-cord-blood-hematopoietic-stem-cell-transplantation-results-in-decreased-relapse-rate-and-improved-survival-compared-to-transplantation-following-standard-reduced-intensity-conditioning
#3
Prashant Sharma, Daniel A Pollyea, Clayton A Smith, Enkhtsetseg Purev, Manali Kamdar, Bradley Haverkos, Daniel Sherbenou, Rachel Rabinovitch, Andrew Hammes, Jonathan A Gutman
The "Minnesota" reduced intensity conditioning (RIC) cord-blood transplantation (CBT) regimen (standard-RIC) of fludarabine (Flu, 200mg/m2 ), cyclophosphamide (Cy, 50mg/kg), and 200cGy or 300cGy total body irradiation (TBI) is the most published RIC CBT regimen. Though well tolerated, high relapse rates remain a concern with this regimen. Intensification of conditioning may reduce relapse without increasing transplant related mortality (TRM). We performed a retrospective cohort comparison of outcomes in adult patients who underwent first double-unit CBT with standard-RIC as compared to the intensified regimen of fludarabine 150mg/m2 , cyclophosphamide 50mg/kg, thiotepa 10mg/kg and 400cGy TBI (intensified-RIC)...
April 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29684563/long-term-results-of-prophylactic-donor-lymphocyte-infusions-for-patients-with-multiple-myeloma-after-allogeneic-stem-cell-transplantation
#4
Maximilian Gröger, Nico Gagelmann, Christine Wolschke, Ute-Marie von Pein, Evgeny Klyuchnikov, Max Christopeit, Axel Zander, Francis Ayuk, Nicolaus Kröger
OBJECTIVE: The major reason for treatment failure after allografting in multiple myeloma (MM) is relapse. Donor lymphocyte infusions are considered a valuable post-transplant strategy mainly for relapsed patients but using them to prevent relapse in MM has been reported rarely. In the present study we examined the efficacy of prophylactic donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in myeloma patients with a long-term follow-up of more than 5 years...
April 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29684562/bmt-following-non-myeloablative-treosulfan-conditioning-is-curative-in-a-murine-model-of-sickle-cell-disease
#5
Divya Devadasan, Chiao-Wang Sun, Erik R Westin, Li-Chen Wu, Kevin M Pawlik, Tim M Townes, Frederick D Goldman
Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative for patients with sickle cell disease (SCD). However, morbidity associated with myeloablative conditioning and graft versus host disease has limited its utility. To this end, autologous HSCT for SCD using lentiviral gene-modified bone marrow (BM) or peripheral blood stem cells has been undertaken, though toxicities of fully ablative conditioning with busulfan and incomplete engraftment have been encountered. Treosulfan, a busulfan analog with a low extra-medullary toxicity profile, has been employed successfully as part of a myeloablative conditioning regimen in the allogeneic setting in SCD...
April 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29683948/hematopoietic-stem-cell-transplantation-from-unrelated-donors-in-2-cases-of-interleukin-10-receptor-deficiency-is-surgery-not-a-requirement
#6
Dilara F Kocacik Uygun, Vedat Uygun, Hayriye Daloğlu, Seda Öztürkmen, Gülsün Karasu, İsmail Reisli, Ersin Sayar, Hasan A Yüksekkaya, Erik-Oliver Glocker, Kaan Boztuğ, Akif Yeşilipek
Mutations in interleukin-10 and its receptors cause infantile inflammatory bowel disease (IBD), a hyperinflammatory disorder characterized by severe, treatment-refractory colitis, multiple abscesses, and enterocutaneous fistulas. Patients with infantile IBD often require several surgical interventions, including complete colectomy, and hematopoietic stem cell transplantation is currently the only known medical therapy. Traditionally, operative management has been preferred before stem cell transplantation because of the latter's increased susceptibility to procedural complications; however, surgical intervention could be delayed, and possibly reconsidered, because our 2 patients with infantile IBD demonstrated a rapid response to treatment via engraftment...
April 20, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29681947/synergistic-integration-of-mesenchymal-stem-cells-and-hydrostatic-pressure-in-the-expansion-and-maintenance-of-human-hematopoietic-progenitor-cells
#7
Yun Gyeong Kang, Jee-Yeong Jeong, Tae-Hee Lee, Ho Sup Lee, Jung-Woog Shin
Ex vivo expansion of hematopoietic stem/progenitor cell (HSPC) has been investigated to improve the clinical outcome of HSPC transplantation. However, ex vivo expansion of HSPCs still faces a major obstacle in that HPSCs tend to differentiate when proliferating. Here, we cocultured HSPCs with mesenchymal stem cells (MSCs) and divided the HSPCs into two fractions according to whether they came into adherent to MSCs or not. Additionally, we used hydrostatic pressure (HP) to mimic the physical conditions in vivo ...
2018: Stem Cells International
https://www.readbyqxmd.com/read/29681820/use-of-eltrombopag-in-improving-poor-graft-function-after-allogeneic-hematopoietic-stem-cell-transplantation
#8
Samip Master, Ashish Dwary, Richard Mansour, Glenn M Mills, Nebu Koshy
Eltrombopag is a thrombopoietin agonist and has been used in aplastic anemia and post-transplantation thrombocytopenia. The c-MPL receptor is present on hematopoietic stem cells. There are no reports of eltrombopag utilization for improving poor graft function in the post-transplant setting. Here were report a case of a young female with post-transplant poor graft function as evident from the low absolute neutrophil count, anemia, and thrombocytopenia on day 60. Eltrombopag was started on day 72 and resulted in improvement in all 3 cell lines...
January 2018: Case Reports in Oncology
https://www.readbyqxmd.com/read/29680516/peripheral-blood-grafts-for-t-cell-replete-haploidentical-transplantation-increase-the-incidence-and-severity-of-cytokine-release-syndrome
#9
Renju V Raj, Mehdi Hamadani, Aniko Szabo, Marcelo C Pasquini, Nirav N Shah, William R Drobyski, Bronwen E Shaw, Wael Saber, J Douglas Rizzo, James Jerkins, Timothy S Fenske, Anita D'Souza, Binod Dhakal, Chao Zhang, Steve Konings, Parameswaran N Hari, Saurabh Chhabra
T-cell replete post-transplant cyclophosphamide (PT-CY)-based protocols have led to increasing use of haploidentical allogeneic hematopoietic cell transplantation (haploHCT). With this approach, bidirectional alloreactivity causing non-engraftment or severe graft-versus-host disease (GVHD) are no longer major barriers to haploHCT. PT-CY eliminates alloreactive lymphocytes but spares CD34+ stem cells and regulatory T lymphocytes, resulting in reliable hematopoietic recovery with relatively low incidence of GVHD...
April 19, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29680515/safety-and-efficacy-of-once-daily-intravenous-busulfan-in-allogeneic-transplantation-a-matched-pair-analysis
#10
Shinichi Kako, Shinichiro Fujiwara, Miki Sato, Shun-Ichi Kimura, Hideki Nakasone, Kazuteru Ohashi, Toshiro Kawakita, Tetsuo Maeda, Takanobu Morishita, Ritsuro Suzuki, Takahiro Fukuda, Tatsuo Ichinohe, Mio Kurata, Yoshiko Atsuta, Yoshinobu Kanda
Compared with 4-times-daily infusion of intravenous busulfan (ivBU4), the safety and efficacy of once-daily infusion of ivBU (ivBU1) has not been fully clarified. We have been routinely using ivBU1 in a conditioning regimen in adult patients with myeloid malignancy who undergo allogeneic hematopoietic stem cell transplantation. In this study, a total of 91 patients who received ivBU1 for 2 days (n = 18) or 4 days (n = 73) in our institutions were compared with 273 control patients who received ivBU4, who were matched for age, sex, performance status, disease risk, conditioning regimen, and donor type, selected from the database of the Japanese Society for Hematopoietic Cell Transplantation using optimal matching algorithms...
April 19, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29679772/efficacy-of-cidofovir-in-treatment-of-bk-virus-induced-hemorrhagic-cystitis-in-post-allogeneic-hematopoietic-cell-transplant-recipients
#11
Eric A Coomes, Amanda Jacques Wolfe, Fotios V Michelis, Dennis Dong-Hwong Kim, Santhosh Thyagu, Auro Viswabandya, Jeffrey H Lipton, Hans A Messner, Uday Deotare
BACKGROUND: BK virus associated hemorrhagic cystitis (BK-HC) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HCT), with incidence up to 70%. Cidofovir is an antiviral agent with growing evidence as a therapeutic intervention. OBJECTIVE: To assess the safety profile and efficacy of intravenous and intravesical cidofovir in allo-HCT patients with BK-HC. METHODS: Retrospective study of the allo-HCT cohort who received cidofovir for symptomatic BK-HC (hematuria with BK viruria or viremia) from January 2010 until March 2017 in a single transplant center in Ontario, Canada...
April 18, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29679523/the-incidence-of-tuberculosis-infection-in-hematopoietic-stem-cell-transplantation-recipients-a-retrospective-cohort-study-from-a-center-in-turkey
#12
Şahika Zeynep Akı, Gülsan Türköz Sucak, Özlem Güzel Tunçcan, Nurdan Köktürk, Esin Şenol
Our results question the role of TST due to low specificity and sensitivity in regions where BCG is mandatory and in patients with hematologic malignancies and suggest that these general guidelines do not seem to apply to all situations. This article is protected by copyright. All rights reserved.
April 21, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29679436/fungal-infections-in-hematopoietic-stem-cell-transplantation-in-children-at-a-pediatric-children-s-hospital-in-argentina
#13
Sergio Miguel Gomez, Miguela Caniza, Alicira Fynn, Cecilia Vescina, Claudia Ruiz, Daniela Iglesias, Fernanda Sosa, Lillian Sung
Our primary objective was to describe the incidence of proven or probable invasive fungal infections (IFIs), a devastating complication of hematopoietic stem cell transplant (HSCT), in HCST in a middle-income country. Secondary objectives were to describe factors associated with IFIs and outcomes. In this single center retrospective study, pediatric patients who underwent a first allogeneic or autologous HSCT from 1998 to 2016 were included. Of the 251 HSCT recipients: 143 transplants were allogeneic and 108 were autologous...
April 20, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29679424/lomentospora-prolificans-fungemia-in-hematopoietic-stem-cell-transplant-patients-first-report-in-south-america-and-literature-review
#14
Fernando D Penteado, Nadia Litvinov, Jaques Sztajnbok, Danilo Y Thomaz, Antonio M Dos Santos, Dewton M Vasconcelos, Adriana L Motta, Flávia Rossi, Juliana F Fernandes, Heloisa Helena S Marques, Gil Benard, João N de Almeida Júnior
Lomentospora prolificans is a filamentous fungus and an emerging pathogen in immunocompromised patients. It is encountered most commonly in Australia, Spain, and USA. We described the first case of Lomentospora prolificans fungemia in South America. The patient was a hematopoietic stem cell transplantation (HSCT) recipient who developed the infection 37 days after stem cells infusion. In addition, we performed a literature review of invasive lomentosporiosis in HSCT patients. This article is protected by copyright...
April 20, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29678639/transplant-outcomes-for-secondary-acute-myeloid-leukemia-alwp-of-the-ebmt-study
#15
Salyka Sengsayadeth, Myriam Labopin, Ariane Boumendil, Finke Jürgen, Ganser Arnold, Stelljes Matthias, Ehninger Gerhard, Beelen Dietrich, Niederwieser Dietger, Blaise Didier, Dreger Peter, Ghulam Mufti, Chevallier Patrice, Audrey Mailhol, Katie S Gatwood, Norbert Gorin, Jordi Esteve, Fabio Ciceri, Frederic Baron, Christoph Schmid, Sebastian Giebel, Mohamad Mohty, Bipin N Savani, Arnon Nagler
Secondary acute myeloid leukemia (sAML) has been associated with inferior outcomes compared to de novo AML. Little is known about patient risk factors and outcomes in sAML after allogeneic hematopoietic stem cell transplantation (HCT), thus this large systemic analysis of the EBMT registry was performed. This study included 4997 patients with sAML who received HCT from 2000-2016. In univariate analysis, the 2-year cumulative incidence of chronic graft versus host disease (GVHD), relapse (RI), and non-relapse mortality (NRM) were 33...
April 17, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29678638/comprehensive-analysis-of-the-activation-and-proliferation-kinetics-and-effector-functions-of-human-lymphocytes-and-antigen-presentation-capacity-of-antigen-presenting-cells-in-xenogeneic-graft-versus-host-disease
#16
Yasufumi Kawasaki, Kazuya Sato, Hiroko Hayakawa, Norihito Takayama, Hirofumi Nakano, Ryoji Ito, Kiyomi Mashima, Iekuni Oh, Daisuke Minakata, Ryoko Yamasaki, Kaoru Morita, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Shin-Ichiro Fujiwara, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
Xenogeneic graft-versus-host disease (GVHD) models in highly immunodeficient mice are currently being used worldwide to investigate human immune responses against foreign antigens in vivo. However, the individual roles of CD4+ and CD8+ T-cells, and donor/host hematopoietic and non-hematopoietic antigen-presenting cells (APCs) in the induction and development of GVHD have not been fully investigated. In the present study, we comprehensively investigated the immune responses of human T-cells and the antigen presentation capacity of donor/host hematopoietic and non-hematopoietic APCs in xenogeneic GVHD models using NOD/Shi-scid-IL2rgnull (NOG) mice...
April 17, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29678553/recipient-and-donor-cells-in-the-graft-versus-solid-tumor-effect-it-takes-two-to-tango
#17
REVIEW
Isabelle Dierckx de Casterlé, An D Billiau, Ben Sprangers
Allogeneic hematopoietic stem cell transplantation (alloHSCT) produces -similar to the long-established graft-versus-leukemia effect- graft-versus-solid-tumor effects. Clinical trials reported response rates of up to 53%, occurring mostly but not invariably in association with full donor chimerism and/or graft-versus-host disease. Although donor-derived T cells are considered the principal effectors of anti-tumor immunity after alloHSCT or donor leukocyte infusion (DLI), growing evidence indicate that recipient-derived immune cells may also contribute...
April 12, 2018: Blood Reviews
https://www.readbyqxmd.com/read/29678144/interferon-alpha-as-antiviral-therapy-in-chronic-active-epstein-barr-virus-disease-with-interstitial-pneumonia-case-report
#18
Jacek Roliński, Ewelina Grywalska, Aleksandra Pyzik, Michał Dzik, Violetta Opoka-Winiarska, Agata Surdacka, Maciej Maj, Franciszek Burdan, Michał Pirożyński, Piotr Grabarczyk, Elżbieta Starosławska
BACKGROUND: Chronic active Epstein-Barr virus (EBV) disease (CAEBV) is defined as a severe, progressive lymphoproliferative disorder associated with active EBV infection persisting longer than 6 months and developing in patients without recognised immunodeficiency. Rarely, interstitial pneumonitis (IP) occurs as a serious complication in CAEBV patients. The standard therapeutic regimen for IP in CAEBV has not yet been defined. Although interferon alpha (IFN-alpha) is known to suppress viral DNA replication by affecting its basal promoter activation process, it is rarely used in CAEBV patients...
April 20, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29677078/therapeutic-outcomes-of-haploidentical-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-severe-aplastic-anemia-a-multicenter-study
#19
Yonghua Li, Fengqi Duan, Haowen Xiao, Xiaoxiong Wu, Shunqing Wang, Duorong Xu, Qifa Liu, Zhiping Fan, Danian Nie, Yongrong Lai, Bingyi Wu, Dongjun Lin, Xin Du, Jianyu Weng, Xin Du, Zujun Jiang, Yan Pang, Lin Ouyang, Zenghui Liu, Leqin Zhang, Na Han, Lixuan Chen, Yang Xiao
BACKGROUND: Haploidentical donor allogeneic hematopoietic stem cell transplantation (HID-HSCT) is an alternative curative treatment for patients with severe aplastic anemia (SAA) who do not have suitable matched related donors (MRD). The aim of this study was to compare the therapeutic outcomes of HID-HSCT with those of MRD-HSCT for SAA. METHODS: A total of 235 SAA patients who underwent HID-HSCT (116) or MRD-HSCT (119) at 11 transplantation centers from January 2007 to January 2016 were included...
April 19, 2018: Transplantation
https://www.readbyqxmd.com/read/29677072/state-of-the-art-role-of-the-dendritic-cell-in-induction-of-allograft-tolerance
#20
Sarah J Rosen, Paul E Harris, Mark A Hardy
Despite decades of research, the induction and maintenance of long-term allograft tolerance without immunosuppression remains an elusive goal in the field of solid organ and cell transplantation. Immunosuppressive medications frequently prevent or minimize acute cellular rejection but have failed to halt anti-donor antibody production and chronic organ rejection. Past efforts aimed at promoting lasting allograft tolerance have focused primarily on peripheral T cell depletion, augmentation of regulatory T cells, or induction via simultaneous hematopoietic stem cell transplantation and facilitation of donor chimerism...
April 19, 2018: Transplantation
keyword
keyword
17903
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"